Restricted accessResearch articleFirst published online 2025-9
Neurodegenerative plasma biomarkers for prediction of hippocampal atrophy in older adults with suspected Alzheimer's disease in Kinshasa,Democratic Republic of Congo
Hippocampal atrophy is a key feature of Alzheimer's disease (AD), but neuroimaging is often inaccessible in low-resource settings. Blood-based biomarkers such as amyloid-β (Aβ42/40), phosphorylated tau-181 (p-tau181), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) may offer a practical alternative, though their utility in African populations remains understudied.
Objective
This study investigated the ability of plasma biomarkers of AD and AD-related dementias—Aβ42/40, p-tau181, NfL, and GFAP—to predict hippocampal atrophy in older adults in Kinshasa, Democratic Republic of Congo.
Methods
Eighty-five adults aged over 65 (40 healthy; 45 suspected AD) were recruited. Core AD (Aβ42/40, p-tau181) and non-specific (NfL, GFAP) biomarkers were analyzed. Hippocampal volumes were measured using MRI. Linear and logistic regressions assessed biomarker differences by age, sex, and neurological status, and predicted hippocampal atrophy.
Results
Elevated p-tau181 was associated with left hippocampal (LH) atrophy (p = 0.020), with 4.2-fold increased odds [OR = 4.2 (1.5–18.4)] of LH atrophy per standard deviation increase. The areas under the curve of plasma biomarkers without clinical covariates to discriminate LH, right hippocampal (RH), and total hippocampal (TH) atrophy ranged from 90%–94%, 76%–82%, and 85%–87%, respectively. Models including clinical covariates and biomarkers improved discrimination to 94%–96% (LH), 81%–84% (RH), and 88%–90% (TH).
Conclusions
Consistent with findings from other settings, core AD plasma biomarkers can effectively predict hippocampal atrophy in a Sub-Saharan African population, supporting their potential for scalable dementia screening where imaging is limited.
RaoYLGanarajaBMurlimanjuBV, et al.Hippocampus and its involvement in Alzheimer’s disease: a review. 3 Biotech2022; 12: 55.
2.
BlennowKZetterbergH. Biomarkers for Alzheimer’s disease: current status and prospects for the future. J Intern Med2018; 284: 643–663.
3.
Babić LekoMNikolac PerkovićMKlepacN, et al.IL-1β, IL-6, IL-10, and TNFα single nucleotide polymorphisms in humans influence susceptibility to Alzheimer’s disease pathology. J Alzheimers Dis2020; 75: 1029–1047.
4.
GiacomucciGMazzeoSBagnoliS, et al.Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in subjective cognitive decline and mild cognitive impairment. J Neurol2022; 269: 4270–4280.
5.
GulisanoWMaugeriDBaltronsMA, et al.Role of amyloid-β and tau proteins in Alzheimer’s disease: confuting the amyloid cascade. J Alzheimers Dis2018; 64: S611–S631.
6.
KimKShinKChangKA. GFAP As a potential biomarker for Alzheimer’s disease: a systematic review and meta-analysis. Cells2023; 12: 1309.
7.
Lyra e SilvaNMGonçalvesRAPascoalTA, et al.Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer’s disease. Transl Psychiatry2021; 11: 251.
8.
JackCRKnopmanDSJagustWJ, et al.Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol2013; 12: 207–216.
9.
HampelHHardyJBlennowK, et al.The amyloid-β pathway in Alzheimer’s disease. Mol Psychiatry2021; 26: 5481–5503.
10.
BraakHDel TrediciK. Spreading of tau pathology in sporadic Alzheimer’s disease along cortico-cortical top-down connections. Cereb Cortex2018; 28: 3372–3384.
11.
MaruszakASilajdžićELeeH, et al.Predicting progression to Alzheimer’s disease with human hippocampal progenitors exposed to serum. Brain2023; 146: 2045–2058.
12.
FortinNJAgsterKLEichenbaumHB. Critical role of the hippocampus in memory for sequences of events. Nat Neurosci2002; 5: 458–462.
13.
XiaoYHuYHuangK. Atrophy of hippocampal subfields relates to memory decline during the pathological progression of Alzheimer’s disease. Front Aging Neurosci2023; 15: 1287122.
14.
ConstantinidesVCParaskevasGPBoufidouF, et al.CSF Aβ42 and Aβ42/Aβ40 ratio in Alzheimer’s disease and frontotemporal dementias. Diagnostics2023; 13: 783.
15.
LewczukPMatzenABlennowK, et al.Cerebrospinal fluid Aβ42/40 corresponds better than Aβ42 to amyloid PET in Alzheimer’s disease. J Alzheimers Dis2017; 55: 813–822.
16.
JanelidzeSTeunissenCEZetterbergH, et al.Head-to-head comparison of 8 plasma amyloid-β42/40 assays in Alzheimer disease. JAMA Neurol2021; 78: 1375–1382.
17.
ThijssenEHLa JoieRStromA, et al.Plasma phosphorylated tau217 and phosphorylated tau181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol2021; 20: 739–752.
18.
IkangaJPatrickSDSchwinneM, et al.Sensitivity of the African neuropsychology battery memory subtests and learning slopes in discriminating APOE4 and amyloid pathology in adult individuals in the democratic Republic of Congo. Front Neurol2024; 15: 1320727.
19.
Malek-AhmadiMSabbaghMNRobertsMC. Development and validation of the Alzheimer’s questionnaire (AQ). J Nat Sci2015; 1: e104.
20.
HallKSGaoSEmsleyCL, et al.Community screening interview for dementia (CSI ‘D’): performance in five disparate study sites. Int J Geriatr Psychiatry2000; 15: 521–531.
21.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association, 2013.
22.
GuerchetMM’BelessoPMouangaAM, et al.Prevalence of dementia in elderly living in two cities of Central Africa: the EDAC survey. Dement Geriatr Cogn Disord2010; 30: 261–268.
23.
IkangaJReyesAKabaD, et al.Prevalence of suspected dementia in a sample of adults living in Kinshasa-Democratic Republic of the Congo. Alzheimers Dement2023; 19: 3783–3793.
24.
VerberkIMWMisdorpEOKoelewijnJ, et al.Characterization of pre-analytical sample handling effects on a panel of Alzheimer’s disease–related blood-based biomarkers: results from the standardization of Alzheimer’s blood biomarkers (SABB) working group. Alzheimers Dement2022; 18: 1484–1497.
25.
WahlundLOBarkhofFFazekasF, et al.A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke2001; 32: 1318–1322.
26.
ClausJJStaekenborgSSHollDC, et al.Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer’s disease: validation in a large memory clinic population. Eur Radiol2017; 27: 3147–3155.
27.
EnkirchSJTraschützAMüllerA, et al.The ERICA score: an MR imaging-based visual scoring system for the assessment of entorhinal cortex atrophy in Alzheimer disease. Radiology2018; 288: 226–233.
28.
MondragónJDCelada-BorjaCBarinagarrementeria-AldatzF, et al.Hippocampal volumetry as a biomarker for dementia in people with low education. Dement Geriatr Cogn Dis Extra2016; 6: 486–499.
29.
HosmerDWJrLemeshowSSturdivantRX. Applied logistic regression. Hoboken, NJ: John Wiley and Sons, Inc., 2013.
30.
JackCRJrAndrewsJSBeachTG, et al.Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s association workgroup. Alzheimers Dement2024; 20: 5143–5169.
31.
IkangaJHickleSSchwinneM, et al.Association between hippocampal volume and African neuropsychology memory tests in adult individuals with probable Alzheimer’s disease in Democratic Republic of Congo. J Alzheimers Dis2023; 96: 395–408.
32.
WangXShiZQiuY, et al.Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK biobank. BMC Med2024; 22: 192.
33.
LiKQuHMaM, et al.Correlation between brain structure atrophy and plasma amyloid-β and phosphorylated tau in patients with Alzheimer’s disease and amnestic mild cognitive impairment explored by surface-based morphometry. Front Aging Neurosci2022; 14: 816043.
34.
ChongJRAshtonNJKarikariTK, et al.Plasma P-tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer’s disease patients with concomitant pathologies. Alzheimers Dement2021; 17: 1649–1662.
35.
LubbenNEnsinkECoetzeeGA, et al.The enigma and implications of brain hemispheric asymmetry in neurodegenerative diseases. Brain Commun2021; 3: fcab211.
36.
StrickerNHDodgeHHDowlingNM, et al.CSF Biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade. Brain Imaging Behav2012; 6: 599–609.
37.
DüzelEBerronDSchützeH, et al.CSF Total tau levels are associated with hippocampal novelty irrespective of hippocampal volume. Alzheimers Dement (Amst)2018; 10: 782–790.
